SITC 2021 | Vaccines are a promising direction for prostate cancer immunotherapy

Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, discusses how patients with prostate cancer have typically been non-responsive to immunotherapy. However, vaccines are an exciting new avenue of research in this field. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.